Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides

Current Opinion in Investigational Drugs

Volumn 2, Issue 4, 2001, Pages 562-573

  Geary, R S ^a   Yu, R Z ^a   Levin, A A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Absorption; Distribution; Metabolism; Pharmacokinetics; Phosphorothioate oligodeoxynucleotide

Indexed keywords

ADENOSINE A1 RECEPTOR; AFOVIRSEN; ALBUMIN; ALICAFORSEN; ALPHA 2 MACROGLOBULIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CGP 69846A; EPI 2010; FOMIVIRSEN; GAG PROTEIN; GPI 2A; IN 3001; INTERCELLULAR ADHESION MOLECULE 1; ISIS 14803; ISIS 2503; ISIS 3521; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PLASMA PROTEIN; PROTEIN BCL 2; PROTEIN KINASE C; RAF PROTEIN; RAS PROTEIN; TRECOVIRSEN; UNCLASSIFIED DRUG;

ASTHMA; BLOOD BRAIN BARRIER; BODY WEIGHT; CHEMISTRY; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; HEPATITIS C VIRUS; HUMAN; IN VIVO STUDY; KIDNEY; LIVER; NONHUMAN; REVIEW; TISSUE METABOLISM;

ANIMALS; BLOOD PROTEINS; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 0035043324     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid
2. Antisense oligonucleotide inhibitors for the treatment of cancer. 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
3. Pharmacokinetic properties of phosphorothioate oligonucleotides
4. Pharmacokinetic properties in humans
5. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-Ras encapsulated in stealth liposomes
6. Pharmacokinetics of antisense oligonucleotides
7. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1
8. 3H-labeled oligonucleotides I. Comparison of a phosphodiester and a phosphorothioate
9. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion
10. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
11. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats
12. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
13. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey
14. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide
15. The pharmacokinetics and toxicity of phosphorothioate oligonucleotides
16. Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302)
17. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects
18. Pharmacokinetic properties of phosphorothioate oligonucleotides in humans
19. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
20. Toxicity of oligodeoxynucleotide therapeutic agents
21. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
22. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice
23. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion
24. 14C-labeled afovirsen sodium in patients with genital warts
25. Pharmacokinetic properties of phosphorothioates in animals - Absorption, distribution, metabolism and elimination
26. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes
27. Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice
28. Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells
29. Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length
30. Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats
31. Pharmacokinetic properties of 2′-O-(2-methoxethyl)-modified oligonucleotide analogs in rats
32. Species and pathway-specific activation of complement by a phosphorothioate oligonucleotide
33. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
34. Effects of intravenous infusion of phosphorothioate oligonucleotides on coagulation, complement activation and hemodynamics
35. Inhibition of coagulation by a phosphorothioate oligonucleotide
36. Activation of the alternative pathway of complement in cynomolgus monkeys following intravenous administration of ISIS 2302, a phosphorothioate oligonucleotide
37. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys
38. The pulmonary route: Potential for the non-parenteral delivery of oligonucleotides?
39. DNA antisense therapy for asthma in an animal model
40. Oligonucleotide therapy of allergic asthma
41. Identification and characterization of second-generation antisense oligonucleotides
42. Antisense oligonucleotide-based therapeutics
43. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding
44. Measurement of macromolecular binding using electrospray mass spectrometry. Determination of disassociation constants for oligonucleotide-serum albumin complexes
45. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex
46. Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice
47. Renal uptake of an 18-mer phosphorothioate oligonucleotide
48. Antisense and kidney
49. Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy
50. Renal disposition characteristics of oligonucleotides modified at terminal linkages in perfused rat kidney
51. Disposition of oligonucleotides in isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake
52. Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotides in monkeys
53. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
54. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: Predominant uptake by scavenger receptors on endothelial cells
55. Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice
56. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues
57. Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue
58. Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice
59. Pharmacokinetic properties in animals
60. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites
61. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides
62. Metabolism of antisense oligonucleotides in rat liver homogenates
63. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase c-alpha, in patients with advanced cancer
64. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of steroid-dependent Crohn's disease
65. A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer
66. Dosing of antisense oligodeoxynucleotides (ONDs) by ideal body weight, rather than actual body weight, may be preferred
67. Anti-BCL2 phosphorothioate G3139 clinical pharmacology: Plasma levels during continuous subcutaneous infusion by HPLC assay
68. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
69. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
70. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer